Sign In
Buy IRON
$70.35
+2.35 (+3.46%)
At Close: Jun 03, 2026
Disc Medicine, Inc. (IRON) Discusses ASH Conference Data Updates and Portfolio Progress Including Anemia and Iron Restriction Programs Transcript
WATERTOWN, Mass., Dec. 06, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel
Disc Medicine, Inc. (IRON) Presents at Jefferies London Healthcare Conference 2025 Transcript
12:13pm, Wednesday, 19'th Nov 2025
Disc Medicine, Inc. ( IRON ) Jefferies London Healthcare Conference 2025 November 19, 2025 9:00 AM EST Company Participants John Quisel - CEO, President & Director Conference Call Participants Jiale S
Portfolio Adjustment: Institutional Heavyweight Exits Biotech Stock
10:24am, Wednesday, 19'th Nov 2025
Bain Capital completely exited its position in Disc Medicine stock during the third quarter
Disc Medicine, Inc. (IRON) Presents at Stifel 2025 Healthcare Conference Transcript
05:58pm, Tuesday, 18'th Nov 2025
Disc Medicine, Inc. ( IRON ) Stifel 2025 Healthcare Conference November 13, 2025 8:40 AM EST Company Participants Jonathan Yu - Chief Opearating Officer Conference Call Participants Stephen Willey - S
Ironveld (LON:IRON) Trading Up 10% – Here’s What Happened
03:30am, Sunday, 02'nd Nov 2025
Shares of Ironveld Plc (LON: IRON - Get Free Report) rose 10% during trading on Friday. The company traded as high as GBX 0.06 and last traded at GBX 0.06. Approximately 259,699,203 shares changed han
Disc Medicine to Participate in Upcoming Investor Conferences
08:30am, Friday, 31'st Oct 2025
WATERTOWN, Mass., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel
Disc Medicine, Inc. (NASDAQ:IRON) Receives Consensus Recommendation of “Moderate Buy” from Analysts
01:56am, Friday, 31'st Oct 2025
Shares of Disc Medicine, Inc. (NASDAQ: IRON - Get Free Report) have received an average recommendation of "Moderate Buy" from the eleven brokerages that are presently covering the firm, MarketBeat rep
What Makes Disc Medicine, Inc. (IRON) a Strong Momentum Stock: Buy Now?
01:00pm, Monday, 27'th Oct 2025
Does Disc Medicine, Inc. (IRON) have what it takes to be a top stock pick for momentum investors? Let's find out.
Does Disc Medicine, Inc. (IRON) Have the Potential to Rally 26.29% as Wall Street Analysts Expect?
10:56am, Wednesday, 22'nd Oct 2025
The consensus price target hints at a 26.3% upside potential for Disc Medicine, Inc. (IRON). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnin
JPMorgan Chase & Co. $JPM Shares Purchased by IRON Financial LLC
04:04am, Tuesday, 21'st Oct 2025
IRON Financial LLC grew its stake in shares of JPMorgan Chase and Co. (NYSE: JPM) by 0.7% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. Th
Disc Medicine Announces Pricing of $250 Million Upsized Public Offering of Common Stock and Pre-Funded Warrants
12:14am, Tuesday, 21'st Oct 2025
WATERTOWN, Mass., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization o
Disc Medicine: NDA Submission And CNPV For Bitopertin Further Boost Shareholder Value
09:15am, Monday, 20'th Oct 2025
Disc Medicine receives a "Strong Buy" rating due to significant progress with bitopertin for EPP and XLP treatment. IRON submitted an NDA for bitopertin under Accelerated Approval, supported by positi
Disc Medicine Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
07:00am, Monday, 20'th Oct 2025
WATERTOWN, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization o
Disc Medicine Provides Update on Hematology Portfolio and Outlines Near-Term Business Objectives and Anticipated Milestones
06:30am, Monday, 20'th Oct 2025
WATERTOWN, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel
